RxDoctor Payments Data

Stephen Badolato, MD

Sports Medicine · Melbourne, FLNPI 1194728832

Payments from drug & device makers

$10,908in general payments, 2019–2025

Across 605 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Amarin Pharma, Inc.$784
  • Lilly USA, LLC$688
  • Johnson & Johnson$644
  • Phathom Pharmaceuticals, Inc.$577
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$10,902100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,908 in reported general payments places this provider in the 75th percentile of 402 sports medicine providers in Florida.

See all sports medicine providers in Florida

Medicare billing

Part B allowed, 2024
$142,299
Medicare patients
550
Services billed
4,144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast12$58,033
OzempicSemaglutide39$49,051
JardianceEmpagliflozin24$24,261
EliquisApixaban22$20,660
RybelsusSemaglutide14$14,226
Celecoxib85$1,931
Gabapentin78$1,903
Levothyroxine Sodium97$1,508
Rosuvastatin Calcium93$1,451
Atorvastatin Calcium97$1,426
Pantoprazole Sodium55$1,134
Nebivolol Hcl16$1,048
Amlodipine Besylate116$1,041
Losartan Potassium58$986
Tamsulosin Hcl54$967

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$474$63,27753 claims
AmgenOtezla$259$58,03312 claims
Boehringer IngelheimJardiance$162$24,26124 claims
PfizerEliquis$319$20,66022 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$1,50897 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 402 sports medicine providers in Florida.

Other sports medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →